NeuroD1 and Dlx2 Viral Vector Glial Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Huntington's disease is currently incurable, and there is no effective treatment to prevent the degeneration of GABAergic medium spiny neurons in the striatum, which are particularly vulnerable to polyglutamine toxicity.
Innovation Solution
The use of a nucleic acid encoding a NeuroD1 polypeptide and a nucleic acid encoding a Dlx2 polypeptide, delivered via an adeno-associated viral vector, to trigger glial cells in the brain's striatum to form functional and integrated GABAergic neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If glial cells are converted to neurons using single transcription factor (NeuroD1 or Dlx2), then some neuronal conversion occurs, but the conversion efficiency and functional integration are insufficient
Solution Approach 1:
The patent combines NeuroD1 and Dlx2 transcription factors into a single therapeutic composition that is co-delivered to glial cells. This merging of two transcription factors enhances the conversion efficiency of glial cells to GABAergic neurons while ensuring proper functional integration, overcoming the insufficiency of using either factor alone.
Solution Approach 2:
The invention uses a composite viral vector system that simultaneously expresses both NeuroD1 and Dlx2 transcription factors. This composite approach creates a synergistic effect that improves neuronal conversion efficiency and functional integration compared to single-factor treatments.
2Reliability
If no treatment is provided for Huntington's disease, then the natural disease progression occurs with degeneration of GABAergic medium spiny neurons, but providing treatment is complex and challenging
Solution Approach 1:
The therapy utilizes the patient's own glial cells as the source for generating replacement neurons. The glial cells are reprogrammed in situ using the NeuroD1/Dlx2 composition, eliminating the need for external cell transplantation and simplifying the treatment protocol while maintaining reliable disease progression control.
Solution Approach 2:
The invention replaces complex mechanical cell transplantation procedures with a molecular-based approach using viral vectors to deliver transcription factors directly to glial cells. This substitution simplifies the treatment mechanism while achieving reliable control over disease progression through precise molecular reprogramming.
3Shape
If GABAergic medium spiny neurons are replaced, then brain architecture can be improved, but the replacement cells must be functionally integrated which is difficult to achieve
Solution Approach 1:
The NeuroD1 and Dlx2 transcription factors are expressed prematurely during the conversion process to guide the development of replacement neurons. This preliminary molecular guidance ensures that the newly generated GABAergic neurons develop proper functional connections and integration characteristics before being fully incorporated into the brain circuitry.
Solution Approach 2:
The therapy changes the molecular parameters of glial cells by introducing specific transcription factors (NeuroD1 and Dlx2), which fundamentally alters their differentiation pathway. This parameter change directs the cells to become functionally integrated GABAergic neurons with appropriate morphology and connectivity, improving both brain architecture and functional integration reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the generation of functional GABAergic neurons that can be integrated into the brain, potentially improving brain architecture, slowing or reversing Huntington's disease progression, and delaying or treating the disease symptoms.
Implementation Method 1
a nucleic acid encoding a NeuroD1 polypeptide and a nucleic acid encoding a Dlx2 polypeptide, delivered via an adeno-associated viral vector, to trigger glial cells in the brain's striatum to form functional and integrated GABAergic neurons
Data Source
Figure 1a~1h
Figure 2a~2d
Figure 3
AI summary
This document provides methods and materials for generating GABAergic neurons in brains. For example, methods and materials for using nucleic acid encoding a NeuroD1 polypeptide and nucleic acid encoding a Dlx2 polypeptide to trigger glial cells (e.g., NG2 glial cells or astrocytes) within the brain (e.g., striatum) into forming GABAergic neurons (e.g., neurons resembling medium spiny neurons such as DARPP32-positive GABAergic neurons) that are functionally integrated into the brain of a living mammal (e.g., a human) are provided.